# US 2026/0060931 A1 · Method for preparation of lisdexamfetamine dimesylate dispersible tablet

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060931 A1
- Document ID: US20260060931A1
- Status: Published application
- Kind: A1
- Application number: 18/931,731
- Filed: 2024-10-30
- Published: 2026-03-05
- Earliest claimed: 2024-09-03
- Applicants: Athena Pharmaceutiques SAS
- Inventors: Mahendra Baliram Chaudhari; Omprakash Doulatram Chandwani; Nitin Pandharinath Nehete; Amol Yuvraj Chaudhari; Anita Kunal Shahane
- Web page: https://patentgrep.com/patent/US20260060931A1

## CPC

- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/2095: {Tabletting processes}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to a method for preparation of a lisdexamfetamine dimesylate dispersible tablet. The method for preparation comprises: dry mixing lisdexamfetamine dimesylate, a diluent, a binder and an anti-static agent to form a dry mix blend; intermediate granular blending of a filler, a cushioning agent, a disintegrating agent, and a sweetener to form an intermediate granular blend; adding and blending the dry mix blend and the intermediate granular blend to form an intermediate drug blend; lubricating the intermediate drug blend with a lubricant to form ready to compress drug granules; and compressing the ready to compress drug granules to form a lisdexamfetamine dimesylate dispersible tablet.

## Claims

### Claim 1

A method for preparation of a lisdexamfetamine dimesylate dispersible tablet, the method comprising:
dry mixing lisdexamfetamine dimesylate, a diluent, a binder and an anti-static agent to form a dry mix blend;
intermediate granular blending of a filler, a cushioning agent, a disintegrating agent, and a sweetener to form an intermediate granular blend;
adding and blending the dry mix blend and the intermediate granular blend to form an intermediate drug blend;
lubricating the intermediate drug blend with a lubricant to form ready to compress drug granules; and
compressing the ready to compress drug granules to form a lisdexamfetamine dimesylate dispersible tablet.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein the lisdexamfetamine dimesylate is present in an amount of about 8 to about 12 percent by weight.

### Claim 3 (depends on 1)

The method as claimed in claim 1, wherein in the dry mixing step:
the diluent is mannitol granular 200SD, and the diluent is present in an amount of about 18 to about 23 percent by weight;
the binder is partially pregelatinized maize starch, and the binder is present in an amount of about 10 to about 20 percent by weight; and
the anti-static agent is colloidal anhydrous silica, and the anti-static agent is present in an amount of about 1 to about 2 percent by weight.

### Claim 4 (depends on 1)

The method as claimed in claim 1, wherein in the intermediate granular blending step:
the filler is mannitol granular 200SD, and the filler is present in an amount of about 28 to about 34 percent by weight;
the cushioning agent is microcrystalline cellulose, and the cushioning agent is present in an amount of about 8 to about 12 percent by weight;
the disintegrating agent is crospovidone, and the disintegrating agent is present in an amount of about 6 to about 10 percent by weight; and
the sweetener is sucralose, and the sweetener is present in an amount of about 1 to about 4 percent by weight.

### Claim 5 (depends on 1)

The method as claimed in claim 1, wherein in the lubrication step, the lubricant is magnesium stearate, and the lubricant is present in an amount of about 1 to about 2 percent by weight.

### Claim 6 (depends on 1)

The method as claimed in claim 1, wherein the dosage amount of the lisdexamfetamine dimesylate dispersible tablet is 10 mg per tablet; 20 mg per tablet; 30 mg per tablet; 40 mg per tablet; 50 mg per tablet; 60 mg per tablet; and 70 mg per tablet.

### Claim 7 (depends on 1)

The method as claimed in claim 1, wherein the dissolution is not less than 75% in 15 minutes.

### Claim 8 (depends on 1)

The method as claimed in claim 1, wherein the friability is not more than 1.5%, the disintegration time is less than 3 minutes at 15° C. to 25° C. (without disc), and the hardness is from about 30 N to about 70 N.

### Claim 9 (depends on 1)

The method as claimed in claim 1, wherein the step of compressing employs direct compression technique in controlled humidity level of NMT 40% to reduce exposure to moisture.

### Claim 10 (depends on 1)

The method as claimed in claim 1, further comprising packaging of lisdexamfetamine dimesylate dispersible tablets in moisture resistant ALU peel off blister package; and/or moisture resistant ALU-ALU blister package.
